You are here

Researchers Identify Multidrug-Resistant E. coli Bacteria in New Jersey Patient

First strain from U.S. patient that resists both carbapenems and colistin

New Jersey researchers have identified what is believed to be the first strain of Escherichia coli bacteria from a patient in the United States that harbored two mobile genes, making it resistant to both broad-spectrum carbapenem antibiotics and colistin, an older antibiotic increasingly used as a last resort for multidrug-resistant infections. Their report was published in mBio, the online open-access journal of the American Society for Microbiology.

The strain of bacteria, isolated in 2014 from a 76-year-old man with a complicated urinary tract infection (UTI) but further analyzed in 2016, was found to carry the genes mcr-1 and blaNDM-5, which confer resistance to colistin and carbapenems, respectively. These genes exist on plasmids, small segments of DNA that are capable of moving from one bacterium to another, potentially spreading antibiotic resistance to other bacterial species. While this strain did respond to other antimicrobial agents and was treated successfully, investigators say the case presents a reminder to monitor and track multidrug-resistant organisms.

“The good news is that this did not cause a major outbreak of drug-resistant infection,” said senior author Barry N. Kreiswirth, PhD. “The bad news is that since this occurred two years ago, there are clearly other strains out there we haven’t detected yet. Both the carbapenem resistance and the colistin resistance genes are on separate plasmids, which means in principle they could spread to other bacteria.”

In August 2014, the patient presented to University Hospital in Newark, New Jersey, with fever and pain in his side. He had emigrated from India to the United States a year before experiencing the symptoms. The man had a history of prostate cancer treated with radiation therapy and subsequently developed recurrent UTIs. He had recently undergone a cystoscopy to examine the bladder. The procedure was complicated by a bladder perforation, requiring surgery to place rubber tubes to help drain the kidneys. Laboratory testing suggested the man had pus in the urine.

The man was started on the antimicrobial drugs piperacillin/tazobactam and vancomycin. A urine sample tested positive for the bacteria Pseudomonas aeruginosa, Citrobacter koseri, and Enterococcus faecium; another urine sample from the tube tested positive for P. aeruginosa, E. coli, Klebsiella pneumoniae, Enterococcus spp., and methicillin-resistant Staphylococcus aureus (MRSA). After six days of antimicrobial therapy, a urine sample was clear of bacteria; the man returned home after another procedure to create a new conduit for urine flow.

Kreiswirth’s laboratory used molecular techniques to identify and compare bacteria in the man’s urine samples. Investigators found that the E. coli strain from the man’s urine sample carried both mcr-1 and blaNDM-5 and harbored resistance to several classes of antibiotics, including aminoglycosides, beta-lactams, chloramphenicol, fluoroquinolones, rifampin, sulfonamides, and tetracycline. Additional testing found that the isolated plasmids were highly similar to others that were reported to be associated with clinical infection in China. The laboratory identified the E. coli strain as a variant of ST405, which is often associated with community-acquired UTIs.

Source: ASM; August 29, 2016.

Recent Headlines

Antibiotics, Statins, and Glucocorticoids All Show Promise
Possible First Treatment Option for Rare Autoimmune Disease of the CNS
New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis
Current, Sole Therapy Not Always Successful/Suitable
Over 1.5 Million Americans Likely to have Wet AMD by 2020 
Potential For Use Against E. Coli, TB, Resistant Bacteria
More Than 32% of Patients Responded in Trial